Drug Discovery World

MARCH 26, 2024

More importantly, it also highlighted that significant challenges remain in selecting the right therapies for the right patients despite the progress made through genomic testing and implementation of circulating tumour (ct) DNA analyses. We were there to present the latest findings from our research.

RNA 64

RNA In-Vivo In-Vitro DNA 64

BioTech 365

MARCH 9, 2021

an important non-canonical DNA secondary structure in vivo and in vitro, G-quadruplexes (GQs) have been widely investigated in many fields including biology, … Continue reading →

Scientist 40

Scientist In-Vivo In-Vitro DNA 40

BioTech 365

SEPTEMBER 20, 2020

SEVILLE, Spain–(BUSINESS WIRE)–Universal Diagnostics (UDX), an in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early, announced today that promising new data for its investigational advanced adenoma (precursor lesions of colorectal cancer) detection blood test and multi-cancer detection (..)

In-Vitro 52

In-Vitro DNA Development 52

Drug Discovery World

APRIL 4, 2023

The platform will perform in vitro transcription translation from DNA-encoded libraries on beads. The collaboration will use Orbit’s peptide display technologies to find peptide leads specific to tumour related targets of interest. Evergreen will focus on subsequent development of the peptides for clinical use.

In-Vitro 52

In-Vitro DNA Development Drugs 52

XTalks

DECEMBER 28, 2023

XTALKS WEBINAR: Impacts of the New IVD Regulation (IVDR) for Manufacturers and Users Live and On-Demand: Tuesday, January 9, 2024, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn how the new In Vitro Diagnostic Regulation (IVDR) impacts manufacturers and users of diagnostic devices.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

pharmaphorum

FEBRUARY 19, 2021

Once someone is infected with HIV it stays with them for life thanks to the retrovirus’s ability to inject its DNA code into the host. We have proven the technology and candidate programs in vitro and in vivo in both small animal models and primate models.

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

XTalks

APRIL 6, 2022

Cancerous cells and tumors release small fragments of DNA into the bloodstream called circulating tumour DNA (ctDNA). The researchers at the Cancer Research UK Cambridge Institute published this data from the LUng cancer CIrculating tumour DNA (LUCID) study in the journal Annals of Oncology. Photo source: Inivata.

DNA 105

DNA In-Vitro Doctors Doctor 105

Bioengineer

JANUARY 16, 2024

Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation.

Genome 119

Genome Genomics Protein In-Vitro 119

pharmaphorum

OCTOBER 29, 2020

The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression.

Development 45

Development DNA In-Vitro Genome 45

Drug Discovery World

OCTOBER 9, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Drug Discovery World

NOVEMBER 2, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Drug Discovery World

OCTOBER 2, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Drug Discovery World

OCTOBER 16, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Drug Discovery World

DECEMBER 13, 2022

To this end, the team designed specific antisense oligonucleotides – small pieces of DNA or RNA that can bind to specific RNA molecules. Encouraged by their in vitro findings, the research team is now proposing translational work by setting up large-scale clinical trials involving patients with FCMD. . Modifying RNA function.

RNA 52

RNA Genetics Gene In-Vitro 52

Roots Analysis

OCTOBER 16, 2023

DNA cloning refers to the process of generating multiple copies of a particular DNA segment. DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence.

DNA 40

DNA Gene Protein In-Vitro 40

Drug Discovery World

SEPTEMBER 29, 2023

In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed. The post Scaling up in vitro transcription: Key results and considerations appeared first on Drug Discovery World (DDW).

In-Vitro 52

In-Vitro Reagent DNA Drugs 52

Drug Discovery World

JANUARY 23, 2023

This action sensitised GBM cells to radiotherapy both in vitro and in vivo (in mouse models). “Our research has revealed cladribine as a radiosensitiser for GBM treatment by drug repurposing, which can offer multiple advantages,” says Prof Youn. “As GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Roots Analysis

AUGUST 15, 2023

Overview of Cell Free Systems Cell-free systems are ­in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells. These expression systems utilize bio machinery harvested from the lysate of disrupted cells for the manufacturing of a wide array of macromolecular and small molecule products.

Protein 52

Protein In-Vitro Production Reagent 52

The Pharma Data

MAY 18, 2021

MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. This companion diagnostic (CDx) provides clinicians with a standardised testing option that uses a comprehensive panel of DNA mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC).

FDA Approval 40

FDA Approval DNA Protein In-Vitro 40

The Pharma Data

DECEMBER 22, 2020

Available since 2017 as an in vitro diagnostic assay (IVD) in Europe and the United States, Japanese clinical geneticists can now have access to this assay to help identify a definitive genetic diagnosis for their patients. SANTA CLARA, Calif.–( –( BUSINESS WIRE )– Agilent Technologies Inc.

Genome 40

Genome Genomics Genetics In-Vitro 40

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

DECEMBER 14, 2020

The current standard of care for GBM consists of de-bulking surgery followed by combined treatments with fractionated ionizing radiation (IR) and the DNA alkylating agent temozolomide (TMZ). . Many drugs fail in clinical trials because of their low blood brain barrier permeability. Lantern’s A.I.

Drugs 52

Drugs Genome Genomics DNA 52

Roots Analysis

JANUARY 14, 2024

It is worth mentioning that in vitro gene expression requires a suitable host for the production of a specific gene product. Notably, biologics have higher success rates than conventional small-molecule drugs owing to lesser off-target toxicity of biologics, which is one of the key reasons of failures in small molecule drugs development.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

XTalks

SEPTEMBER 30, 2020

The team sequenced DNA from 659 critically ill COVID-19 patients and 534 controls with mild or asymptomatic disease. The two studies were recently published online in the journal Science, both of which were led by Jean-Laurent Casanova, an infectious disease geneticist at Rockefeller University. Mutational Errors in COVID-19 Patients.

Antibody 135

Antibody Genetics Research In-Vitro 135

The Pharma Data

MARCH 22, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Financial details of the agreement were not disclosed. Pfizer expects supply to be available to support orders in April 2022, and supply will continue throughout 2022, pending regulatory authorization or approval and according to country needs.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Production 52

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

Drug Discovery World

OCTOBER 23, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

Production 52

Production In-Vitro Reagent DNA 52

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA 52

RNA Protein DNA In-Vivo 52

Pfizer

AUGUST 15, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1 FDA Emergency Use Authorization Statement.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? DDW’s Megan Thomas finds out. He says: “In recent years, the field has seen exponential growth, which has outpaced the rate at which new professionals enter.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

Drug Discovery World

APRIL 11, 2024

Treatment of BRCA2-deficient but not wild-type DLD1 cells with BSM-1516 resulted in cell cycle arrest accompanied by DNA damage signalling and accumulation of chromatin-bound RPA32, a marker of ssDNA. It was announced that the next AACR Annual Meeting will take place in Chicago on 25-30 April 2025.

HR 52

HR Antibody In-Vitro DNA 52

Drug Discovery World

MARCH 14, 2023

Applications of in vitro transcribed (IVT) RNA in mRNA therapeutics have exciting implications for modern medicine, as the ability to easily change mRNA sequences provides a flexible platform to create robust therapeutics against a wide variety of chronic and infectious diseases. Figure 2: TheraPure GMP products for mRNA production 2.

Production 52

Production RNA DNA Manufacturing 52

Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision. PAXLOVID is currently approved or authorized for conditional or emergency use in more than 70 countries to treat COVID-19.

Marketing 75

Marketing Production Drugs Licensing 75

Drug Discovery World

JANUARY 17, 2024

Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer. As such there is a need to develop fast and accurate methods to assess drug safety and efficacy, facilitating early success or failure.

Medicine 59

Medicine DNA Genome Genomics 59

Drug Discovery World

JANUARY 12, 2023

The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Organoids are 3D tissue models consisting of multiple cell types that could bridge the gap between traditional 2D in vitro cultures and the actual in vivo tissue of the body. What are organoids? .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

Pharmaceutical Technology

NOVEMBER 22, 2022

mRNA vaccines can be made more quickly than traditional vaccine platforms because they are produced using an in vitro synthetic process that does not require the time-consuming growth or removal of cells and proteins. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. The UK Government is behind this effort.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130